Harry D. Pedersen, MBA

Founder, President & Chief Executive Officer

Mr. Pedersen has over 25 years of leadership experience in the life sciences industry including business development, pre-clinical and clinical development, strategy and finance. Mr. Pedersen was the co-founder and chief business officer of ChemGenex Pharmaceuticals and, prior to that, was the vice president of business development at Matrix Pharmaceuticals. From 1986-1997 Mr. Pedersen served various roles of increasing responsibility in licensing, business development and strategic planning with Sanofi-Aventis.

Jackie Walling, MBChB, PhD

Chief Scientific Officer

Dr. Walling has extensive experience in the clinical development of anticancer drugs and drugs for rare diseases. She is the owner of JW Consulting. Formerly the VP Clinical Development at BioMarin she has also held positions of increasing responsibility at Eli Lilly, and Tularik. Prior to this she did laboratory research on the pharmacology of anticancer drugs. Dr. Walling holds BSc and PhD degrees from the University of Southampton, UK and an MBChB from the University of Bristol.

Wang Shen, PhD

Vice President, Research & Development

Dr. Wang Shen has worked as a medicinal chemist in biotech/pharmaceutical industry for over 20 years. Most recently, Dr. Shen founded KanionUSA Inc. in 2009 and has served as its President.  Dr. Shen has led or co-led medicinal chemistry teams to have identified 5 clinical stage molecules.  Dr. Shen has authored more than 40 publications in peer-reviewed journals and is a co-inventor in more than 50 issued or published patent applications.



5/23/18: NewGen Granted patent for NT-113 in Europe


Corporate Headquarters:
3475 Edison Way, Suite R
Menlo Park, CA 94025